Zhejiang Tianyu Pharmaceutical's (SHE:300702) subsidiary, Zhejiang Jingsheng Pharmaceutical, received a certificate of suitability from Europe for the sitagliptin phosphate active pharmaceutical ingredient.
The certificate shows that the product met the region's quality standards and is a step toward the product being approved to be sold within Europe.
Sitagliptin phosphate was developed to treat patients with Type 2 diabetes mellitus.
The company's shares closed 3% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments